The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation.
Recently it has been shown that the expression of the immunoproteasome increased in proportion to the degree of chronic inflammation in both the liver cell cytoplasm and nuclei in liver biopsies from patients who had chronic active hepatitis or cirrhosis. In the present study, biopsies from patients with steatohepatitis, with or without Mallory-Denk body (MDB) formation, were studied by immunofluorescent staining. Normal liver showed colocalization of FAT10, LMP2, LMP7, and MECL-1 at the mitochondria. Only LMP2 and LMP7 were found in the cell nuclei. Liver biopsies from patients with steatohepatitis and MDB formation, and a case of hepatocellular carcinoma forming MDBs in the tumor cells, showed colocalization of FAT10 and ubiquitin with LMP2, LMP7 and MECL-1 within the MDB. This indicates involvement of the immunoproteasome in MDB formation in steatohepatitis cases and in a case of HCC forming MDBs. Prior studies have shown that the immunoproteasome was involved in drug-induced MDB formation using the same immunofluorescent colocalization approach as was used on these human liver biopsies. The increase in the immunoproteasome subunit proteins was made at the expense of the 26S proteasome. This indicates that the shift from the 26S to the immunoproteasome had occurred in the MDB positive hepatocytes.
Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA 90509, USA. sfrench@labiomed.org
B A
BA
French
J
J
Oliva
F
F
Bardag-Gorce
S W
SW
French
D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology; D002467:Cell Nucleus / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D005234:Fatty Liver / Q000378:metabolism* / Q000473:pathology; D019084:Fluorescent Antibody Technique, Indirect; D006519:Hepatitis, Alcoholic / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007162:Immunoproteins / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology; D008930:Mitochondria, Liver / Q000378:metabolism; D009124:Muscle Proteins / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011506:Proteins / Q000378:metabolism*
D007162:Immunoproteins; C027596:Mallory body protein, human; D009124:Muscle Proteins; C085047:PSME1 protein, human; D011506:Proteins; C071313:LMP-2 protein; D003546:Cysteine Endopeptidases; C077436:LMP7 protein; C098948:PSMB10 protein, human; D046988:Proteasome Endopeptidase Complex
Exp Mol Pathol. 2010 Jun;88(3):376-9
20206621
Biochim Biophys Acta. 2011 Feb;1809(2):80-7
20674813
J Exp Med. 1994 Mar 1;179(3):901-9
8113682
Ann N Y Acad Sci. 2008 Dec;1147:242-53
19076446
Exp Mol Pathol. 2007 Oct;83(2):160-8
17531972
World J Hepatol. 2010 Aug 27;2(8):295-301
21161012
Nat Rev Immunol. 2010 Jan;10(1):73-8
20010787
World J Gastroenterol. 2010 Mar 21;16(11):1344-8
20238401
Exp Mol Pathol. 2008 Apr;84(2):113-21
18281034
Novartis Found Symp. 2007;287:4-14; discussion 14-20
18074628
Biochem Biophys Res Commun. 2010 Jun 25;397(2):301-6
20510670
Exp Mol Pathol. 2008 Apr;84(2):102-12
18280469
Hepatology. 2008 Feb;47(2):613-24
18098314
Exp Mol Pathol. 2010 Jun;88(3):353-62
20223233
Exp Mol Pathol. 2010 Aug;89(1):1-8
20433827
Semin Liver Dis. 1981 Aug;1(3):217-31
7051303
Hepatology. 1981 Jan-Feb;1(1):76-83
6269976
J Cell Biol. 2010 Dec 27;191(7):1367-80
21173115